Drug intelligence / Profile preview

DXC022

Development stage: Preclinical
Lead developer: Hangzhou DAC Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DXC022 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Hangzhou DAC Biotech for the treatment of solid tumors. It specifically targets Guanylate cyclase C (GUCY2C), a transmembrane receptor that is highly expressed in gastrointestinal malignancies, including colorectal and gastric cancers, while having limited expression in normal extra-intestinal tissues. The drug consists of a GUCY2C-targeting monoclonal antibody conjugated to a cytotoxic payload, intended to induce cell death upon internalization into target tumor cells. DXC022 utilizes Hangzhou DAC Biotech's proprietary ADC platform technology to optimize the therapeutic index and target specificity.

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on DXC022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DXC022.

Explore the full profile